AIMT Aimmune Therapeutics Inc.

32.62
-0.38  -1%
Previous Close 33
Open 33.2
Price To Book 13.54
Market Cap 2,064,835,627
Shares 63,299,682
Volume 1,243,531
Short Ratio
Av. Daily Volume 925,651
Stock charts supplied by TradingView

NewsSee all news

  1. Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas,

  2. Aimmune to Participate in Three Upcoming Investor Conferences

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in

  3. New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge

    — Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients — Aimmune Therapeutics, Inc.

  4. Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

    —New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers— Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a

  5. New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - March 25, 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
Advisory Committee meeting September 13, 2019 voted in favor of supporting approval. PDUFA date late-January 2020.
AR101
Peanut Allergy
Phase 2 trial to be completed 2H 2020.
AR 201
Egg Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 data due 2020.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas,

  2. Aimmune to Participate in Three Upcoming Investor Conferences

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in

  3. New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge

    — Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients — Aimmune Therapeutics, Inc.

  4. Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

    —New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers— Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a

  5. New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy

  6. AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

    —Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo— Aimmune Therapeutics, Inc. (NASDAQ:AIMT),

  7. Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

    --Webcast and conference call today at 4:30 p.m. ET-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced

  8. Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will

  9. Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the

  10. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6,

  11. Aimmune to Present at the Cantor Global Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will

  12. FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune's PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC)

  13. Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company's common stock. The U.S.

  14. Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

    PALM BEACH, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) -- According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based

  15. Aimmune to Participate in Three Investor Conferences in September

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in